Answers are grounded in this paper and cite their sources.
We are issuing this call-to-action to the diabetes community (health care providers [HCPs], people with type 1 diabetes [PwT1D] and their caregivers, and payers) to fully recognize and implement the advances made over the last 10+ years in automated insulin delivery (AID) systems. Pivotal trials and real-world data provide robust and compelling evidence for the benefits of using AID systems, going beyond those of continuous glucose monitors (CGM) when added to a regimen of multiple daily insulin (MDI) injections and/or conventional pump therapy (with or without concomitant CGM).
No takes yet. Share an insight, caveat, or question.
Saboo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: